Postural instability in Parkinson’s disease: the adrenergic hypothesis and the locus coeruleus

References

• Langston JW. The Parkinson’s complex: Parkinsonism is just the tip of the iceberg. Ann. Neurol.59(4), 591–596 (2006).
   PubMed Web of Science ®Google Scholar
• Hoehn MM, Yahr MD. Parkinsonism – onset progression and mortality. Neurology17(5), 427–442 (1967).
   PubMed Web of Science ®Google Scholar
• Bloem BR, Grimbergen YAM, Cramer M, Willemsen M, Zwinderman AH. Prospective assessment of falls in Parkinson’s disease. J. Neurol.248(11), 950–958 (2001).
   PubMed Web of Science ®Google Scholar
• Horak FB, Macpherson JM. Postural orientation and equilibrium. In: Handbook of Physiology – Section 12: Exercise: Regulation and Integration of Multiple Systems. Rowell LB, Shepherd JP (Eds). Oxford University Press, NY, USA 255–292 (1996).
   Google Scholar
• Bloem BR, Bhatia KP. Gait and balance in basal ganglia disorders. In: Clinical Disorders of Balance, Posture and Gait. Bronstein AM, Brandt T, Nutt JG, Woollacott MH (Eds). Arnold, London, UK 173–206 (2004).
   Google Scholar
• Bloem BR, Visser JE, Allum JH. Posturography. In: Handbook of Clinical Neurophysiology. Hallet M (Ed.). Elsevier Science BV, Amsterdam, The Netherlands 295–336 (2003).
   Google Scholar
• Bakker M, Allum JHJ, Visser JE et al. Postural responses to multidirectional stance perturbations in cerebellar ataxia. Exp. Neurol.202(1), 21–35 (2006).
   PubMed Web of Science ®Google Scholar
• Horak FB, Dimitrova D, Nutt JG. Direction-specific postural instability in subjects with Parkinson’s disease. Exp. Neurol.193(2), 504–521 (2005).
   PubMed Web of Science ®Google Scholar
• Bloem BR, Beckley DJ, van Dijk JG et al. Medium latency stretch reflexes in young-onset parkinsons-disease and MPTP-induced Parkinsonism. J. Neurol. Sci.123(1–2), 52–58 (1994).
   PubMedGoogle Scholar
• Nardone A, Schieppati M. Balance in Parkinson’s disease under static and dynamic conditions. Mov. Disord.21(9), 1515–1520 (2006).
   PubMed Web of Science ®Google Scholar
• Brooks DJ, Ibanez V, Sawle GV et al. Differing patterns of striatal 18F-dopa uptake in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Ann. Neurol.28(4), 547–555 (1990).
   PubMed Web of Science ®Google Scholar
• Davidson DL, Yates CM, Mawdsley C, Pullar IA, Wilson H. CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders. J. Neurol. Neurosurg. Psychiatr.40(12), 1136–1141 (1977).
   PubMed Web of Science ®Google Scholar
• Vingerhoets FJG, Schulzer M, Caine DB, Snow BJ. Which clinical sign of Parkinson’s disease best reflects the nigrostriatal lesion? Ann. Neurol.41(1), 58–64 (1997).
   PubMed Web of Science ®Google Scholar
• Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. Tremor in Parkinson’s disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology60(4), 601–605 (2003).
   PubMedGoogle Scholar
• Bloem BR, Beckley DJ, Vanvugt JPP et al. Long-latency postural reflexes are under supraspinal dopaminergic control. Mov. Disord.10(5), 580–588 (1995).
   PubMedGoogle Scholar
• Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl Acad. Sci. USA80(14), 4546–4550 (1983).
   PubMed Web of Science ®Google Scholar
• Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science219(4587), 979–980 (1983).
   PubMed Web of Science ®Google Scholar
• Tetrud JW, Langston JW, Garbe PL, Ruttenber AJ. Mild Parkinsonism in persons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neurology39(11), 1483–1487 (1989).
   PubMedGoogle Scholar
• Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) – 7 cases. Neurology35(7), 949–956 (1985).
   PubMed Web of Science ®Google Scholar
• Agid Y, Graybiel AM, Ruberg M et al. The efficacy of levodopa treatment declines in the course of Parkinson’s disease: do nondopaminergic lesions play a role? Adv. Neurol.53, 83–100 (1990).
   PubMedGoogle Scholar
• Bonnet AM, Loria Y, Sainthilaire MH, Lhermitte F, Agid Y. Does long-term aggravation of Parkinson’s-disease result from nondopaminergic lesions. Neurology37(9), 1539–1542 (1987).
   PubMed Web of Science ®Google Scholar
• Klawans HL. Individual manifestations of Parkinson’s disease after ten or more years of levodopa. Mov. Disord.1(3), 187–192 (1986).
   PubMedGoogle Scholar
• Bloem BR, Beckley DJ, van Dijk JG, Zwinderman AH, Remler MP, Roos RAC. Influence of dopaminergic medication on automatic postural responses and balance impairment in Parkinson’s disease. Mov. Disord.11(5), 509–521 (1996).
   PubMed Web of Science ®Google Scholar
• Horak FB, Frank J, Nutt J. Effects of dopamine on postural control in parkinsonian subjects: scaling, set, and tone. J. Neurophysiol.75(6), 2380–2396 (1996).
   PubMed Web of Science ®Google Scholar
• Bloem BR, van Vugt JP, Beckley DJ. Postural instability and falls in Parkinson’s disease. Adv. Neurol.87, 209–223 (2001).
   PubMed Web of Science ®Google Scholar
• Beckley DJ, Bloem BR, Singh J, Remler MP, Wolfe NS, Roos RA. Postural reflexes in patients on long-term neuroleptic medication. Clin. Neurol. Neurosurg.93(2), 119–122 (1991).
   PubMedGoogle Scholar
• Schieppati M, Nardone A. Free and supported stance in Parkinson’s disease. The effect of posture and ‘postural set’ on leg muscle responses to perturbation, and its relation to the severity of the disease. Brain114(3), 1227–1244 (1991).
   PubMed Web of Science ®Google Scholar
• Scholz E, Diener HC, Noth J, Friedemann H, Dichgans J, Bacher M. Medium and long latency EMG responses in leg muscles: Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr.50(1), 66–70 (1987).
   PubMedGoogle Scholar
• Braak H, Bohl JR, Muller CM, Rub U, De Vos RAI, Del Tredici K. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson’s disease reconsidered. Mov. Disord.21(12), 2042–2051 (2006).
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Pathology of Parkinsons-disease – changes other than the nigrostriatal pathway. Mol. Chem. Neuropathol.14(3), 153–197 (1991).
   PubMed Web of Science ®Google Scholar
• Plaha P, Gill SS. Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson’s disease. Neuroreport16(17), 1883–1887 (2005).
   PubMed Web of Science ®Google Scholar
• Stefani A, Lozano AM, Peppe A et al. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson’s disease. Brain130, 1596–1607 (2007).
   PubMed Web of Science ®Google Scholar
• Strafella AP, Lozano AM, Ballanger B, Poon YY, Lang AE, Moro E. rCBF changes associated with PPN stimulation in a patient with Parkinson’s disease: a PET study. Mov. Disord.23(7), 1051–1054 (2008).
   PubMed Web of Science ®Google Scholar
• Kuo SH, Kenney C, Jankovic J. Bilateral pedunculopontine nuclei strokes presenting as freezing of gait. Mov. Disord.23(4), 616–619 (2008).
   PubMed Web of Science ®Google Scholar
• Pahapill PA, Lozano AM. The pedunculopontine nucleus and Parkinson’s disease. Brain123, 1767–1783 (2000).
   PubMed Web of Science ®Google Scholar
• Mann DMA. The locus coeruleus and its possible role in aging and degenerative disease of the human central nervous-system. Mech. Ageing Dev.23(1), 73–94 (1983).
   PubMed Web of Science ®Google Scholar
• Singewald N, Philippu A. Release of neurotransmitters in the locus coeruleus. Prog. Neurobiol.56(2), 237–267 (1998).
   PubMed Web of Science ®Google Scholar
• Baker KG, Tork I, Hornung JP, Halasz P. The human locus coeruleus complex: an immunohistochemical and three dimensional reconstruction study. Exp. Brain Res.77(2), 257–270 (1989).
   PubMed Web of Science ®Google Scholar
• Chan-Palay V, Asan E. Quantitation of catecholamine neurons in the locus coeruleus in human brains of normal young and older adults and in depression. J. Comp. Neurol.287(3), 357–372 (1989).
   PubMed Web of Science ®Google Scholar
• German DC, Walker BS, Manaye K, Smith WK, Woodward DJ, North AJ. The human locus coeruleus: computer reconstruction of cellular distribution. J. Neurosci.8(5), 1776–1788 (1988).
   PubMed Web of Science ®Google Scholar
• Vijayashankar N, Brody H. Quantitative study of the pigmented neurons in the nuclei locus coeruleus and subcoeruleus in man as related to aging. J. Neuropathol. Exp. Neurol.38(5), 490–497 (1979).
   PubMedGoogle Scholar
• Loughlin SE, Foote SL, Grzanna R. Efferent projections of nucleus locus-coeruleus – morphological subpopulations have different efferent targets. Neuroscience18(2), 307–319 (1986).
   PubMed Web of Science ®Google Scholar
• Mason ST, Fibiger HC. Regional topography within noradrenergic locus coeruleus as revealed by retrograde transport of horseradish peroxidase. J. Comp. Neurol.187(4), 703–724 (1979).
   PubMedGoogle Scholar
• Björklund A, Skagerberg G. Descending monoaminergic projections to the spinal cord. In: Brain Stem Control of Spinal Mechanisms. Sjölund B, Björklund A (Eds). Elsevier, Amsterdam, The Netherlands 55–88 (1982).
   Google Scholar
• Barbeau H, Rossignol S. Initiation and modulation of the locomotor pattern in the adult chronic spinal cat by noradrenergic, serotonergic and dopaminergic drugs. Brain Res.546(2), 250–260 (1991).
   PubMed Web of Science ®Google Scholar
• Kiehn O, Hultborn H, Conway BA. Spinal locomotor-activity in acutely spinalized cats induced by intrathecal application of noradrenaline. Neurosci. Lett.143(1–2), 243–246 (1992).
   PubMedGoogle Scholar
• Bloem BR, Hausdorff JA, Visser JE, Giladi N. Falls and freezing of gait in Parkinson’s disease: a review of two interconnected, episodic phenomena. Mov. Disord.19(8), 871–884 (2004).
   PubMed Web of Science ®Google Scholar
• Aston-Jones G, Rajkowski J, Cohen J. Locus coeruleus and regulation of behavioral flexibility and attention. Prog. Brain Res.126, 165–182 (2000).
   PubMed Web of Science ®Google Scholar
• Berridge CW, Waterhouse BD. The locus coeruleus–noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res. Brain Res. Rev.42(1), 33–84 (2003).
   PubMed Web of Science ®Google Scholar
• Clark CR, Geffen GM, Geffen LB. Catecholamines and attention. I: animal and clinical studies. Neurosci. Biobehav. Rev.11(4), 341–352 (1987).
   PubMed Web of Science ®Google Scholar
• Valentino RJ, Van Bockstaele E. Convergent regulation of locus coeruleus activity as an adaptive response to stress. Eur. J. Pharmacol.583(2–3), 194–203 (2008).
   PubMed Web of Science ®Google Scholar
• Bloem BR, Overeem S, van Dijk JG. Syncopal falls, drop attacks and their mimics. In: Clinical Disorders of Balance, Posture and Gait. Bronstein AM, Brandt T, Nutt JG, Woollacott MH (Eds). Arnold, London, UK 286–316 (2004).
   Google Scholar
• Walberg F. Paths descending from the brain stem – an overview. In: Brain Stem Control of Spinal Mechanisms. Sjölund B, Björklund A (Eds). Elsevier, Amsterdam, The Netherlands 1–27 (1982).
   Google Scholar
• Pompeiano O. Relationship of noradrenergic locus coeruleus neurones to vestibulospinal reflexes. Prog. Brain Res.80, 329–343 (1989).
   PubMedGoogle Scholar
• Pompeiano O, Horn E, d’Ascanio P. Locus coeruleus and dorsal pontine reticular influences on the gain of vestibulospinal reflexes. Prog. Brain Res.88, 435–462 (1991).
   PubMedGoogle Scholar
• Barnes CD, Manzoni D, Pompeiano O, Stampacchia G. Responses of locus coeruleus and subcoeruleus neurons to sinusoidal neck rotation in decerebrate cat. Neuroscience31(2), 371–392 (1989).
   PubMedGoogle Scholar
• Horak FB, Shupert CL, Dietz V, Horstmann G. Vestibular and somatosensory contributions to responses to head and body displacements in stance. Exp. Brain Res.100(1), 93–106 (1994).
   PubMed Web of Science ®Google Scholar
• Beckley DJ, Bloem BR, Remler MP, Roos RA, van Dijk JG. Long latency postural responses are functionally modified by cognitive set. Electroencephalogr. Clin. Neurophysiol.81(5), 353–358 (1991).
   PubMedGoogle Scholar
• Horak FB. Postural orientation and equilibrium: what do we need to know about neural control of balance to prevent falls? Age Ageing35, 7–11 (2006).
   Web of Science ®Google Scholar
• Carpenter MG, Allum JH, Honegger F, Adkin AL, Bloem BR. Postural abnormalities to multidirectional stance perturbations in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr.75(9), 1245–1254 (2004).
   PubMed Web of Science ®Google Scholar
• Horak FB, Diener HC. Cerebellar control of postural scaling and central set in stance. J. Neurophysiol.72(2), 479–493 (1994).
   PubMed Web of Science ®Google Scholar
• Timmann D, Horak FB. Prediction and set-dependent scaling of early postural responses in cerebellar patients. Brain120, 327–337 (1997).
   PubMed Web of Science ®Google Scholar
• Snijders AH, van de Warrenburg BP, Giladi N, Bloem BR. Neurological gait disorders in elderly people: clinical approach and classification. Lancet Neurol.6(1), 63–74 (2007).
   PubMed Web of Science ®Google Scholar
• Chan-Palay V, Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson’s disease with and without dementia and depression. J. Comp. Neurol.287(3), 373–392 (1989).
   PubMed Web of Science ®Google Scholar
• Hoogendijk WJG, Pool CW, Troost D, Vanzwieten E, Swaab DF. Image analyzer-assisted morphometry of the locus coeruleus in alzheimers disease, parkinsons disease and amyotrophic lateral sclerosis. Brain118, 131–143 (1995).
   PubMedGoogle Scholar
• German DC, Manaye KF, White CL 3rd et al. Disease-specific patterns of locus coeruleus cell loss. Ann. Neurol.32(5), 667–676 (1992).
   PubMed Web of Science ®Google Scholar
• Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol.60(3), 337–341 (2003).
   PubMed Web of Science ®Google Scholar
• Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res.318(1), 121–134 (2004).
   PubMed Web of Science ®Google Scholar
• Bloem BR, Munneke M, Mazibrada G et al. The nature of falling in progressive supranuclear palsy. Mov. Disord.19, 359–360 (2004).
   Google Scholar
• Mann DM, Yates PO, Hawkes J. The pathology of the human locus ceruleus. Clin. Neuropathol.2(1), 1–7 (1983).
   PubMed Web of Science ®Google Scholar
• Tohgi H, Abe T, Takahashi S, Ueno M, Nozaki Y. Cerebrospinal fluid dopamine, norepinephrine, and epinephrine concentrations in Parkinson’s disease correlated with clinical symptoms. Adv. Neurol.53, 277–282 (1990).
   PubMedGoogle Scholar
• Tohgi H, Abe T, Saheki M, Yamazaki K, Murata T. Concentration of catecholamines and indoleamines in the cerebrospinal fluid of patients with vascular parkinsonism compared to Parkinson’s disease patients. J. Neural Transm.104(4–5), 441–449 (1997).
   PubMed Web of Science ®Google Scholar
• Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson’s disease. Brain Res.275(2), 321–328 (1983).
   PubMed Web of Science ®Google Scholar
• Martignoni E, Blandini F, Petraglia F, Pacchetti C, Bono G, Nappi G. Cerebrospinal-fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide-Y levels in Parkinson’s-disease, multiple system atrophy and dementia of the Alzheimer type. J. Neural Transm. Park. Dis. Dement. Sect.4(3), 191–205 (1992).
   PubMedGoogle Scholar
• Kish SJ, Shannak KS, Rajput AH, Gilbert JJ, Hornykiewicz O. Cerebellar norepinephrine in patients with Parkinsons-disease and control subjects. Arch. Neurol.41(6), 612–614 (1984).
   PubMedGoogle Scholar
• Cash R, Dennis T, Lheureux R, Raisman R, Javoyagid F, Scatton B. Parkinsons-disease and dementia – norepinephrine and dopamine in locus-ceruleus. Neurology37(1), 42–46 (1987).
   PubMed Web of Science ®Google Scholar
• Sofic E, Riederer P, Gsell W, Gavranovic M, Schmidtke A, Jellinger K. Biogenic amines and metabolites in spinal cord of patients with Parkinson’s disease and amyotrophic lateral sclerosis. J. Neural Transm. Park Dis. Dement. Sect.3(2), 133–142 (1991).
   PubMedGoogle Scholar
• Chia LG, Cheng FC, Kuo JS. Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson’s disease. J. Neurol. Sci.116(2), 125–134 (1993).
   PubMed Web of Science ®Google Scholar
• Brooks DJ. Imaging non-dopaminergic function in Parkinson’s disease. Mol. Imaging Biol.9(4), 217–222 (2007).
   PubMedGoogle Scholar
• Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain128(Pt 6), 1314–1322 (2005).
   PubMed Web of Science ®Google Scholar
• Colosimo C, Craus A. Noradrenergic drugs for levodopa-induced dyskinesia. Clin. Neuropharmacol.26(6), 299–305 (2003).
   PubMedGoogle Scholar
• Boomsma F, van der Hoorn FA, Man in ‘t Veld AJ, Schalekamp MA. Determination of D,L-threo-3,4-dihydroxyphenylserine and of the D- and L-enantiomers in human plasma and urine. J. Chromatogr.427(2), 219–227 (1988).
   PubMedGoogle Scholar
• Reches A. Noradrenergic influences on dopaminergic function and the pharmacology of dihydroxyphenylserine (DOPS): implication for Parkinson’s disease. Clin. Neuropharmacol.8(3), 249–259 (1985).
   PubMed Web of Science ®Google Scholar
• Freeman R, Young J, Landsberg L, Lipsitz L. The treatment of postprandial hypotension in autonomic failure with 3,4-DL-threo-dihydroxyphenylserine. Neurology47(6), 1414–1420 (1996).
   PubMed Web of Science ®Google Scholar
• Biaggioni I, Robertson D. Endogenous restoration of noradrenaline by precursor therapy in dopamine-β-hydroxylase deficiency. Lancet2(8569), 1170–1172 (1987).
   PubMed Web of Science ®Google Scholar
• Kaufmann H, Oribe E, Yahr MD. Differential effect of L-threo-3,4-dihydroxyphenylserine in pure autonomic failure and multiple system atrophy with autonomic failure. J. Neural Transm. Park Dis. Dement. Sect.3(2), 143–148 (1991).
   PubMedGoogle Scholar
• Azuma T, Suzuki T, Sakoda S et al. Effect of long-term L-threo-3,4-dihydroxyphenylserine administration on α2-adrenergic receptors in platelet membranes in neurologic disorders. Acta Neurol. Scand.84(1), 46–50 (1991).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Sakoda S, Ueji M et al. Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study. Neurology34(11), 1446–1450 (1984).
   PubMedGoogle Scholar
• Teelken AW, van den Berg GA, Muskiet FA, Staal-Schreinemachers AL, Wolthers BG, Lakke JP. Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson’s disease. J. Neural Transm. Park Dis. Dement. Sect.1(3), 177–188 (1989).
   PubMedGoogle Scholar
• Yamamoto M, Ogawa N, Ujike H. Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson’s disease. J. Neurol. Sci.73(1), 39–44 (1986).
   PubMedGoogle Scholar
• Bartholini J, Constantinidis J, Puig M, Tissot R, Pletscher A. The stereoisomers of 3,4-dihydroxyphenylserine as precursors of norepinephrine. J. Pharmacol. Exp. Ther.193(2), 523–532 (1975).
   PubMed Web of Science ®Google Scholar
• Puig M, Bartholini G, Pletscher A. Formation of noradrenaline in the rat brain from the four stereoisomers of 3,4-dihydroxyphenylserine. Naunyn Schmiedebergs Arch. Pharmacol.281(4), 443–446 (1974).
   PubMedGoogle Scholar
• Gibson CJ. Increase in norepinephrine turnover after tyrosine or DL-threo-3,4-dihydroxyphenylserine (DL-threo-DOPS). Life Sci.42(1), 95–102 (1988).
   PubMedGoogle Scholar
• Karai N, Kato T, Katsuyama M, Nakamura M, Katsube J. Effect of L-threo-3,4-dihydroxyphenylserine(L-threo-DOPS) on brain and serum MHPG levels in mice: evidence for NE formation in CNS. Life Sci.40(23), 2261–2268 (1987).
   PubMedGoogle Scholar
• Tohgi H, Abe T, Takahashi S, Takahashi J, Ueno M, Nozaki Y. Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients. Neurosci. Lett.116(1–2), 194–197 (1990).
   PubMed Web of Science ®Google Scholar
• Tohgi H, Abe T, Takahashi S. The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients. J. Neural Transm. Park Dis. Dement. Sect.5(1), 27–34 (1993).
   PubMedGoogle Scholar
• Quinn NP, Pelmutter JS, St.Louis M, Marsden D. Acute administration of DL-threo-DOPS does not affect the freezing phenomenon in Parkinson’s disease. Neurology34(Suppl. 1), 149 (1984) (Abstract).
   Google Scholar
• Narabayashi H, Kondo T. Results of a double blind study of L-threo-DOPS in Parkinsonism. In: Recent Developments in Parkinson’s Disease. Fahn Sea (Ed.). Maxmillan, New Jersey, USA 279–291 (1987).
   Google Scholar
• Narabayashi H, Yokochi F, Ogawa T, Igakura T. Analysis of L-threo-3, 4-dihydroxyphenylserine effect on motor and psychological symptoms in Parkinson’s disease. No To Shinkei43(3), 263–268 (1991).
   PubMedGoogle Scholar
• Ogawa N, Kuroda H, Yamamoto M, Nukina I, Ota Z. Improvement in freezing phenomenon of Parkinson’s disease after DL-threo-3, 4-dihydroxyphenylserine. Acta Med. Okayama38(3), 301–304 (1984).
   PubMedGoogle Scholar
• Freeman R, Landsberg L, Young J. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Neurology53(9), 2151–2157 (1999).
   PubMed Web of Science ®Google Scholar
• Hasegawa Y, Mukai E, Matsusoka Y et al. Effect of oral L-threo-DOPS on orthostatic hypotension in Parkinson’s disease. Mov. Disord.12(Suppl. 1), 88 (1997) (Abstract).
   Google Scholar
• Mizoguchi K, Tanaka M, Yokoo H, Yoshida M, Tsuda A. L-threo-3,4-dihydroxyphenylserine, a noradrenaline precursor, inhibits dopamine release and metabolism in the rat striatum in vivo. Experientia48(11–12), 1133–1134 (1992).
   PubMedGoogle Scholar
• Man in ‘t Veld AJ, Boomsma F, van den Meiracker AH, Julien C, Lenders J, Schalekamp MA. D,L-threo-3,4-dihydroxyphenylserine restores sympathetic control and cures orthostatic hypotension in dopamine β-hydroxylase deficiency. J. Hypertens. Suppl.6(4), S547–S549 (1988).
   PubMedGoogle Scholar
• Ghika J, Tennis M, Hoffman E, Schoenfeld D, Growdon J. Idazoxan treatment in progressive supranuclear palsy. Neurology41(7), 986–991 (1991).
   PubMed Web of Science ®Google Scholar
• Manson AJ, Iakovidou E, Lees AJ. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson’s disease. Mov. Disord.15(2), 336–337 (2000).
   PubMed Web of Science ®Google Scholar
• Fox SH, Lang AE, Brotchie JM. Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to Phase IIa clinical studies: keys to success and roads to failure. Mov. Disord.21(10), 1578–1594 (2006).
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Katner JS, Nelson DL et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology27(5), 699–711 (2002).
   PubMed Web of Science ®Google Scholar
• Ben Itzhak R, Giladi N, Gruendlinger L, Hausdorff JM. Can methylphenidate reduce fall risk in community-living older adults? A double-blind, single-dose cross-over study. J. Am. Geriatr. Soc.56(4), 695–700 (2008).
   PubMedGoogle Scholar
• Auriel E, Hausdorff JM, Herman T, Simon ES, Giladi N. Effects of methylphenidate on cognitive function and gait in patients with Parkinson’s disease: a pilot study. Clin. Neuropharmacol.29(1), 15–17 (2006).
   PubMed Web of Science ®Google Scholar
• Pollak L, Dobronevsky Y, Prohorov T, Bahunker S, Rabey JM. Low dose methylphenidate improves freezing in advanced Parkinson’s disease during off-state. J. Neural Transm. Suppl.72, 145–148 (2007).
   PubMed Web of Science ®Google Scholar
• Devos D, Krystkowiak P, Clement F et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr.78(5), 470–475 (2007).
   PubMed Web of Science ®Google Scholar
• Nutt JG, Carter JH, Carlson NE. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial. Arch. Neurol.64(3), 319–323 (2007).
   PubMedGoogle Scholar
• D’Amato RJ, Zweig RM, Whitehouse PJ et al. Aminergic systems in Alzheimer’s disease and Parkinson’s disease. Ann. Neurol.22(2), 229–236 (1987).
   PubMedGoogle Scholar
• Iacono RP, Kuniyoshi SM, Ahlman JR, Zimmerman GJ, Maeda G, Pearlstein RD. Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkinson’s patients with severe postural instability and gait disorders. J. Neural Transm.104(4–5), 451–459 (1997).
   PubMedGoogle Scholar
• Klein P, Lees A, Stern G. Consequences of chronic 5-hydroxy-tryptophan in parkinsonian instability of gait and balance and in other neurological disorders. Adv. Neurol.45, 603–604 (1987).
   PubMedGoogle Scholar
• Bloem BR, Geurts AC, Hassin-Baer S, Giladi N. Treatment of gait and balance disorders. In: Therapeutics of Parkinson’s Disease and Other Mov. Disord. Hallet M, Poewe WH (Eds). John Wiley & Sons, Chichester, UK (2008).
   Google Scholar
• Burns RS, LeWitt PA, Ebert MH, Pakkenberg H, Kopin IJ. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N. Engl. J. Med.312(22), 1418–1421 (1985).
   PubMed Web of Science ®Google Scholar
• Burleigh A, Horak F, Nutt J, Frank J. Levodopa reduces muscle tone and lower extremity tremor in Parkinson’s disease. Can. J. Neurol. Sci.22(4), 280–285 (1995).
   PubMed Web of Science ®Google Scholar
• Rocchi L, Chiari L, Horak FB. Effect of levodopa and DBS on anticipatory postural adjustments in subjects with Parkinson’s disease. Mov. Disord.19, S187–S188 (2004).
   Google Scholar
• Beckley DJ, Panzer VP, Remler MP, Ilog LB, Bloem BR. Clinical correlates of motor performance during paced postural tasks in Parkinson’s disease. J. Neurol. Sci.132(2), 133–138 (1995).
   PubMedGoogle Scholar
• Dick JP, Rothwell JC, Berardelli A et al. Associated postural adjustments in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr.49(12), 1378–1385 (1986).
   PubMed Web of Science ®Google Scholar
• Frank JS, Horak FB, Nutt J. Centrally initiated postural adjustments in parkinsonian patients on and off levodopa. J. Neurophysiol.84(5), 2440–2448 (2000).
   PubMed Web of Science ®Google Scholar
• Burleigh-Jacobs A, Horak FB, Nutt JG, Obeso JA. Step initiation in Parkinson’s disease: influence of levodopa and external sensory triggers. Mov. Disord.12(2), 206–215 (1997).
   PubMed Web of Science ®Google Scholar